Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

New oligonucleotide facility is designed to support "Make in India" initiative by synthesizing Co-Primers® in-house. Attendees of new ribbon-cutting event expected to include representatives from NGOs and government leaders SALT LAKE CITY , Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt.

Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations. Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Jade Montgomery - H.C.

Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.20 per share a year ago.

Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates

SALT LAKE CITY , Nov. 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Results: Revenue of $0.6 million, which declined from $2.5 million during the prior year primarily due to timing of grant revenue recognition.

Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results

SALT LAKE CITY , Nov. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth and delivering a presentation at the MEDICA 2024 trade fair in Düsseldorf, Germany on November 11-14. MEDICA has become the largest medical B2B trade fair in the world, attracting 83,000 visitors and over 5,300 exhibitors from almost 70 countries.

Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024

SALT LAKE CITY , Oct. 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2024 results on Thursday, November 7, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast

SALT LAKE CITY , Oct. 21, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be hosting a booth at Africa Health/Medlab Africa in Cape Town, South Africa on October 22-24, 2024. The conference website describes it as the largest gathering of healthcare companies, technology, products and services in the sub-Saharan region, catering to an audience of distributors, government representatives, laboratory executives, and purchasing/procurement managers from the South African Development Community region and around the world, who attend to meet with world-class suppliers and manufacturers.

Co-Diagnostics, Inc. to Host Booth at Medlab Africa in Cape Town on Oct 22-24, 2024

SALT LAKE CITY , Oct. 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be hosting a booth at the Utah Health Care Association/Utah Center for Assisted Living (UHCA/UCAL) Convention & Expo at the Mountain America Expo Center in Sandy, Utah on October 2-3, 2024. The UHCA/UCAL Convention includes sessions and events for executive leadership, administrators, corporate personnel, owners, and Directors of Nursing for skilled nursing, assisted living and intermediate care facilities, and will include an expo for companies to exhibit their products and services relevant to these industries.

Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3

SALT LAKE CITY , Sept. 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced Company representatives will be accompanying Utah Governor Cox and the Governor's Office of Economic Opportunity, as part of the latest World Trade Center (WTC) Utah trade mission to South Korea and Japan from September 24-October 5.

Co-Diagnostics, Inc. to Accompany Utah Governor and WTC Utah on Trade Mission to South Korea and Japan

SALT LAKE CITY , Sept. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has performed an in silico analysis of the Co-Dx™ Logix Smart® Mpox (2-Gene) RUO test to evaluate the possible impact of clade Ib mpox on the test.

Co-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test

SALT LAKE CITY , Aug. 15, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth at the 16th Annual Next Generation Dx Summit, held virtually and in-person in Washington, D.C. on August 19-21, 2024.

Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Jade Montgomery - H.C. Wainwright Operator Good day, and welcome to the Co-Diagnostics Second Quarter 2024 Earnings Conference Call.

Co-Diagnostics, Inc. (CODX) Q2 2024 Earnings Call Transcript

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago.

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Tops Revenue Estimates

SALT LAKE CITY , August 8, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Results: Revenue of $2.7 million, up from $0.2 million during the prior year primarily due to the achievement of certain milestones under various grant agreements the company was awarded Operating expenses of $10.1 million decreased by 13.7% from the prior year due to lower stock-based compensation expense, bad debt expense, and expenses related to clinical trials for the Co-Dx PCR platform Operating loss of $7.7 million compared to operating loss of $12.0 million in 2023 Net loss of $7.6 million, compared to net loss of $8.9 million in the prior year, representing a loss of $0.25 per fully diluted share, compared to a loss of $0.31 per fully diluted share in the prior year Adjusted EBITDA loss of $5.9 million compared to $9.6 million in the prior year Cash, cash equivalents, and marketable securities of $44.9 million as of June 30, 2024 Second Quarter and Recent 2024 Business Highlights: Submitted first 510(k) application to the U.S. Food and Drug Administration (FDA) for the Co-Dx™ PCR Pro™ Platform, which includes the Co-Dx PCR Pro instrument and the Co-Dx PCR COVID-19 test for over-the-counter (OTC) use Inaugurated a new manufacturing facility in South Salt Lake to manufacture our patented Co-Primers® oligonucleotides, the Co-Dx™ PCR Pro™ instrument, and test cups for the new Co-Dx PCR platform Expanded Co-Dx vector control technology to a 15th U.S. state, Nevada, which includes Vector Smart® PCR tests in environmental surveillance of mosquito pools for mosquito-borne illnesses Attended and participated in the FIME 2024 trade show in Miami Beach, Florida, which included exhibitors from 116 countries and over 15,000 professional attendees, to display the new Co-Dx PCR platform "We are very pleased by the progress Co-Diagnostics has made so far this year," said Dwight Egan, Co-Diagnostics' Chief Executive Officer.

Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results

SALT LAKE CITY , July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting and expo held July 28-August 1, 2024, in Chicago, IL. Co-Dx will also be holding a special company presentation to discuss the role of its new at-home and point-of-care Co-Dx™ PCR platform* in closing the global diagnostics gap for an array of potential indications, including tuberculosis (TB).

Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago

SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2024 results on Thursday, August 8, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast

SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that use of the Company's vector control technology will expand to the 15th U.S. state following an installation in Nevada next week. Co-Dx vector control technology includes Vector Smart® PCR tests used in environmental (non-diagnostic) surveillance of mosquito pools for mosquito-borne illnesses like West Nile virus, Zika, dengue and chikungunya.

Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States

SALT LAKE CITY , June 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21. FIME is described as the Americas' leading medical trade expo for medical device and product purchasers, for establishing new supplier relationships, and for strengthening business ties with the global medical device and equipment market, with exhibitors from 116 countries and more than 15,000 expected professional attendees.

Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY , June 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has completed its first U.S. Food and Drug Administration (FDA) application for 510(k) clearance for the Co-Dx™ PCR Pro™ instrument, and the Co-Dx PCR COVID-19 Test for over-the-counter (OTC) use. Co-Diagnostics completed the submission via the FDA's electronic Submissions Template And Resource (eSTAR) system, and have received the acknowledgement from the FDA that the 510(k) application was received.

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the Co-Diagnostics First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.

Co-Diagnostics, Inc. (CODX) Q1 2024 Earnings Call Transcript

SALT LAKE CITY , May 9, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Dx," or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Results: Revenue of $0.5 million, down from $0.6 million during the prior year.

Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results

SALT LAKE CITY , April 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast

SALT LAKE CITY , April 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth and delivering a presentation at the 9th Asia Pacific Region Conference (APRC) of the International Union Against Tuberculosis and Lung Disease on April 26-29, 2024 in Taipei, Taiwan. The theme for the 2024 conference is "Shaping a Safer World Through High-Quality Holistic Healthcare," reflecting the organizers' vision to discuss current evidence, share ideas and information, and accelerate innovation.

Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan

Ribbon-cutting included support from Mayor Wood of South Salt Lake and other dignitaries SALT LAKE CITY , April 12, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it held the ribbon cutting event for its new manufacturing facility yesterday in the City of South Salt Lake. The facility has been designed to manufacture the Co-Dx Pro™ instrument and test cups for the new platform*, as well as the Company's patented Co-Primers™ chemistry that underpins the Company's PCR diagnostic tests.

Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event

SALT LAKE CITY , April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Company, Richard Abbott (President) served as the President of Advanced Conceptions, Inc., a wholly-owned subsidiary of Co-Diagnostics since December 2021, and has been instrumental in establishing the teams and technology of the Co-Dx PCR platform*.

News for Co-Diagnostics Stock (CODX)